BioGraph 55
PrivateLast Round
Series B
Jun 1, 2024
Total Funding Raised
$20.1M
Company Overview
BioGraph 55 is a drug discovery company that develops novel B-cell therapies and drugs for autoimmunity and immuno-oncology using a proprietary spatial 'omics' platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioGraph 55 Comparables
Compare BioGraph 55 with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Rondo Therapeutics | 78% | |
| Tizona Therapeutics | 71% | |
| Xencor, Inc. | 68% |
BioGraph 55 Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 1, 2024 | ||||
| Series A | Mar 1, 2023 |
BioGraph 55 Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pathway Bioventures | Series B, Series A |
| Red Tree Venture Capital | Series B, Series A |
| Pfizer Ventures | Series B, Series A |
BioGraph 55 Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about BioGraph 55's valuation, stock price, and market status.
Is BioGraph 55 a public or private company?
BioGraph 55 is a private company.
What is the current stock price of BioGraph 55?
BioGraph 55 is a private company, so its shares have no public market price. Caplight tracks BioGraph 55's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BioGraph 55 worth (valuation)?
Valuation information for BioGraph 55 is not publicly available.
Can I buy BioGraph 55 stock?
BioGraph 55 shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BioGraph 55's last funding round?
BioGraph 55's most recent funding round was Series B on June 1, 2024.
Who are the main investors in BioGraph 55?
Key investors in BioGraph 55 include Red Tree Venture Capital.
Will BioGraph 55 IPO soon?
No public IPO plans have been announced for BioGraph 55.
How can I track BioGraph 55 secondary market activity?
Caplight tracks bids, offers, and trades in BioGraph 55's shares on secondary markets.